EANO guideline on the diagnosis and management of meningiomas
R Goldbrunner, P Stavrinou, MD Jenkinson… - Neuro …, 2021 - academic.oup.com
Meningiomas are the most common intracranial tumors. Yet, only few controlled clinical trials
have been conducted to guide clinical decision making, resulting in variations of …
have been conducted to guide clinical decision making, resulting in variations of …
FAPI PET/CT: will it end the hegemony of 18F-FDG in oncology?
RJ Hicks, PJ Roselt, KG Kallur, RW Tothill… - Journal of Nuclear …, 2021 - Soc Nuclear Med
For over 40 years, 18F-FDG has been the dominant PET tracer in neurology, cardiology,
inflammatory diseases, and, most particularly, oncology. Combined with the ability to …
inflammatory diseases, and, most particularly, oncology. Combined with the ability to …
[HTML][HTML] A vaccine targeting mutant IDH1 in newly diagnosed glioma
Abstract Mutated isocitrate dehydrogenase 1 (IDH1) defines a molecularly distinct subtype of
diffuse glioma,–. The most common IDH1 mutation in gliomas affects codon 132 and …
diffuse glioma,–. The most common IDH1 mutation in gliomas affects codon 132 and …
Fibroblast activation protein–specific PET/CT imaging in fibrotic interstitial lung diseases and lung cancer: a translational exploratory study
M Röhrich, D Leitz, FM Glatting, AK Wefers… - Journal of nuclear …, 2022 - Soc Nuclear Med
Interstitial lung diseases (ILDs) comprise over 200 parenchymal lung disorders. Among
them, fibrosing ILDs, especially idiopathic pulmonary fibrosis, are associated with a poor …
them, fibrosing ILDs, especially idiopathic pulmonary fibrosis, are associated with a poor …
[HTML][HTML] PET molecular imaging in drug development: the imaging and chemistry perspective
The positron emission tomography (PET) with selective radioligands advances the drug
discovery and development process at the earlier and late stages by revealing information …
discovery and development process at the earlier and late stages by revealing information …
FET PET radiomics for differentiating pseudoprogression from early tumor progression in glioma patients post-chemoradiation
Simple Summary Following chemoradiation with alkylating agents in glioma patients,
structural magnetic resonance imaging (MRI) may suggest tumor progression which …
structural magnetic resonance imaging (MRI) may suggest tumor progression which …
Artificial intelligence and machine learning in nuclear medicine: future perspectives
Artificial intelligence and machine learning based approaches are increasingly finding their
way into various areas of nuclear medicine imaging. With the technical development of new …
way into various areas of nuclear medicine imaging. With the technical development of new …
[HTML][HTML] Updates in IDH-wildtype glioblastoma
JM Melhem, J Detsky, MJ Lim-Fat, JR Perry - Neurotherapeutics, 2022 - Elsevier
Glioblastoma is the most aggressive primary brain tumor with a poor prognosis. The 2021
WHO CNS5 classification has further stressed the importance of molecular signatures in …
WHO CNS5 classification has further stressed the importance of molecular signatures in …
A randomized phase II trial of veliparib, radiotherapy, and temozolomide in patients with unmethylated MGMT glioblastoma: the VERTU study
Background Temozolomide offers minimal benefit in patients with glioblastoma with
unmethylated O 6-methylguanine-DNA methyltransferase (MGMT) promoter status, hence …
unmethylated O 6-methylguanine-DNA methyltransferase (MGMT) promoter status, hence …
Imaging biomarkers for clinical applications in neuro-oncology: current status and future perspectives
FY Chiu, Y Yen - Biomarker Research, 2023 - Springer
Biomarker discovery and development are popular for detecting the subtle diseases.
However, biomarkers are needed to be validated and approved, and even fewer are ever …
However, biomarkers are needed to be validated and approved, and even fewer are ever …